PMID- 36399316
OWN - NLM
STAT- MEDLINE
DCOM- 20230207
LR  - 20240314
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 40
IP  - 2
DP  - 2023 Feb
TI  - Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular 
      Carcinoma: A Systematic Review and Meta-analysis.
PG  - 521-549
LID - 10.1007/s12325-022-02371-3 [doi]
AB  - INTRODUCTION: Programmed cell death 1 (PD-1) and programmed cell death ligand 1 
      (PD-L1) inhibitors have been increasingly employed for the treatment of various 
      cancers in clinical practice. This study aimed to systematically evaluate the 
      efficacy and safety of PD-1/PD-L1 inhibitors for advanced hepatocellular 
      carcinoma (HCC). METHODS: PubMed, EMBASE, Cochrane library, Web of Science, and 
      Abstracts of American Society of Clinical Oncology proceedings databases were 
      searched. Objective response rate (ORR), disease control rate (DCR), median 
      progression-free survival (PFS), median overall survival (OS), and incidence of 
      adverse events (AEs) and drug withdrawal were pooled. Odds ratio (OR) and hazard 
      ratio (HR) were calculated to analyze the difference in the ORR, DCR, PFS, and OS 
      between groups. RESULTS: Among the 14,902 initially identified papers, 98 studies 
      regarding use of PD-1/PD-L1 inhibitors in advanced HCC were included. Based on 
      different criteria of response in solid tumors, the pooled ORR, DCR, and median 
      PFS was 16-36%, 54-74%, and 4.5-6.8 months, respectively. The pooled median OS 
      was 11.9 months. Compared to multitarget tyrosine kinase inhibitors (TKIs), 
      PD-1/PD-L1 inhibitors monotherapy significantly increased ORR (OR 2.73, 
      P < 0.00001) and OS (HR 0.97, P = 0.05), and PD-1/PD-L1 inhibitors combined with 
      TKIs significantly increased ORR (OR 3.17, P < 0.00001), DCR (OR 2.44, 
      P < 0.00001), PFS (HR 0.58, P < 0.00001), and OS (HR 0.58, P < 0.00001). The 
      pooled incidence of all-grade AEs, grade >/= 3 AEs, and drug withdrawal was 71%, 
      25%, and 7%, respectively. CONCLUSION: On the basis of the present systematic 
      review and meta-analysis, PD-1/PD-L1 inhibitors should be the preferred treatment 
      choice for advanced HCC owing to their higher antitumor effect and improved 
      outcomes.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part 
      of Springer Nature.
FAU - Liu, Yuwei
AU  - Liu Y
AD  - Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of 
      Northern Theater Command, Shenyang, No. 83 Wenhua Road, Shenyang, 110840, 
      Liaoning, People's Republic of China.
AD  - Postgraduate College, Shenyang Pharmaceutical University, Shenyang, 110016, 
      People's Republic of China.
FAU - Pan, Jiahui
AU  - Pan J
AD  - Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of 
      Northern Theater Command, Shenyang, No. 83 Wenhua Road, Shenyang, 110840, 
      Liaoning, People's Republic of China.
AD  - Postgraduate College, Shenyang Pharmaceutical University, Shenyang, 110016, 
      People's Republic of China.
FAU - Gao, Fangbo
AU  - Gao F
AD  - Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of 
      Northern Theater Command, Shenyang, No. 83 Wenhua Road, Shenyang, 110840, 
      Liaoning, People's Republic of China.
AD  - Postgraduate College, Shenyang Pharmaceutical University, Shenyang, 110016, 
      People's Republic of China.
FAU - Xu, Wentao
AU  - Xu W
AD  - Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of 
      Northern Theater Command, Shenyang, No. 83 Wenhua Road, Shenyang, 110840, 
      Liaoning, People's Republic of China.
AD  - Postgraduate College, Shenyang Pharmaceutical University, Shenyang, 110016, 
      People's Republic of China.
FAU - Li, Hongyu
AU  - Li H
AD  - Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of 
      Northern Theater Command, Shenyang, No. 83 Wenhua Road, Shenyang, 110840, 
      Liaoning, People's Republic of China.
FAU - Qi, Xingshun
AU  - Qi X
AUID- ORCID: 0000-0002-9448-6739
AD  - Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of 
      Northern Theater Command, Shenyang, No. 83 Wenhua Road, Shenyang, 110840, 
      Liaoning, People's Republic of China. xingshunqi@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221118
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Programmed Cell Death 1 Receptor
MH  - *Liver Neoplasms/drug therapy
MH  - *Lung Neoplasms/drug therapy
OTO - NOTNLM
OT  - Adverse event
OT  - Disease control rate
OT  - Meta-analysis
OT  - Objective response rate
OT  - Overall survival
OT  - PD-1
OT  - PD-L1
OT  - Progression-free survival
EDAT- 2022/11/19 06:00
MHDA- 2023/02/08 06:00
CRDT- 2022/11/18 11:18
PHST- 2022/08/31 00:00 [received]
PHST- 2022/10/24 00:00 [accepted]
PHST- 2022/11/19 06:00 [pubmed]
PHST- 2023/02/08 06:00 [medline]
PHST- 2022/11/18 11:18 [entrez]
AID - 10.1007/s12325-022-02371-3 [pii]
AID - 10.1007/s12325-022-02371-3 [doi]
PST - ppublish
SO  - Adv Ther. 2023 Feb;40(2):521-549. doi: 10.1007/s12325-022-02371-3. Epub 2022 Nov 
      18.